Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Smoking Cessation Program in the Preadmission Clinic

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Dr. Frances Chung, University Health Network, Toronto Identifier:
First received: March 21, 2011
Last updated: June 7, 2016
Last verified: June 2016

Main Hypothesis: The multifaceted intervention (preoperative counseling, pharmacotherapy by varenicline and follow up by quit line) in the preoperative clinic is more effective than the simple preoperative smoking intervention (brief advice and provision of information about the quit lines ) in terms of short-term and long-term quit rates

Objectives: To evaluate the effectiveness and feasibility of a multifaceted intervention (preoperative counseling, pharmacotherapy by varenicline and follow up by the quit line) in the preoperative clinic to help surgical patients quit smoking perioperatively and for the long-term.

Condition Intervention
Drug: Smoking cessation counselling group
Other: Control group:

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Smoking Cessation Program in the Preadmission Clinic:The Combination of Counseling, Pharmacotherapy and Quit Line

Resource links provided by NLM:

Further study details as provided by University Health Network, Toronto:

Primary Outcome Measures:
  • pre-surgery counseling for quit smoking [ Time Frame: 1 year after surgery ]

    In order to determine the prevalence of abstinence in long-term follow up (4, 12, 24 and 52 weeks), patients will be asked the following questions:

    • Have you been abstinent from smoking for the past four weeks? (4-week abstinence)
    • Do you currently smoke cigarettes everyday? (point prevalence)
    • Have you been abstinent from smoking since the last time you quit smoking? (continuous abstinence)

Secondary Outcome Measures:
  • perioperative complications [ Time Frame: 3 months after surgery ]
    Secondary outcome measures that will be studied are as follows: The changes in the number of cigarettes consumed per day or 'stage of change' at 4, 12, 24 and 52 weeks after the initial assigned target quit date. The incidence of perioperative complications (until 30 days after surgery) as well as medication-related adverse events (and serious adverse events) will also be recorded (only those who in the smoking-cessation program).

Estimated Enrollment: 296
Study Start Date: December 2010
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Smoking cessation group
Counselling, Pharmacotherapy and Smokers Help Line
Drug: Smoking cessation counselling group
The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
Control group
Brief informatin about quitting and smokers help line
Other: Control group:
Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients who smoke more than 10 cigarettes per day for more than 1 year
  • And had no period of smoking abstinence longer than 3 months in the past year.
  • Patients who are scheduled to have any elective surgery next 7 to 60 days. Patients > 18 years of age

Exclusion Criteria:

  • Patients unwilling or unable to give informed consent
  • Patients who are pregnant and breast feeding
  • Patients with any psychiatric disorder
  • Patients who used nicotine replacement / bupropion within previous 3 months
  • Cardiovascular disease within the past 6 months
  • Any serious or unstable disease within the past 6 months
  • Drug or alcohol abuse within the past year.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01320462

Canada, Ontario
Toronto Western Hospital, Department of Aneshtesia
Toronto, Ontario, Canada, M5T2S8
Mount Sinai Hospital, Department of Anesthesia
Toronto, Ontario, Canada
Sponsors and Collaborators
University Health Network, Toronto
Principal Investigator: Frances Chung, FRCPC University Health Network, Toronto
  More Information

Responsible Party: Dr. Frances Chung, Staff Anesthesiologist, University Health Network, Toronto Identifier: NCT01320462     History of Changes
Other Study ID Numbers: WS836526
Study First Received: March 21, 2011
Last Updated: June 7, 2016

Keywords provided by University Health Network, Toronto:
champix processed this record on April 25, 2017